SME · BSE SMEListed
SPECIALITY MEDICINES LIMITED IPO: dates, price band, lot size, objects of the issue
Get analyst updates on this IPO
Analyst updates come by email.What changed since listing, from SEBI-registered research analysts.
By continuing you agree to the Terms and Privacy policy
Key facts
- Issue size at the upper band
- ₹29.14 crore
- Listing date
- Mon 30 Mar 2026
- BSE daily price file for Mon 30 Mar 2026
Timeline (IST)
- OpensFri 20 Mar 2026, 10:00 am IST confirmedProspectus dated Wed 25 Mar 2026, page 2
- ClosesTue 24 Mar 2026 confirmedProspectus dated Wed 25 Mar 2026, page 2
- UPI mandate cut-offNot stated in the prospectus Prospectus dated Wed 25 Mar 2026
- AllotmentWed 25 Mar 2026 by T+3 schedule
- Refund and unblockFri 27 Mar 2026 by T+3 schedule
- Shares to dematFri 27 Mar 2026 by T+3 schedule
- ListingMon 30 Mar 2026 confirmedBSE daily price file for Mon 30 Mar 2026
Objects of the issue
| Object | Amount |
|---|---|
| Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje: Manda, Tal. Umargam, Dist. Valsad, Gujarat | ₹12.68 crore |
| Product Registration in International Markets and Product Development for sale in international markets | ₹2.99 crore |
| Funding for Marketing and Promotional Activities | ₹1.66 crore |
| To Meet Working Capital Requirements. | ₹8.00 crore |
| General Corporate Purposes | ₹25.00 lakh |
| Total | ₹25.58 crore |
Prospectus dated Wed 25 Mar 2026, page 87
Company and promoters
As described in the prospectus
We are engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases.
Prospectus dated Wed 25 Mar 2026, page 22
Promoters
- 2 individual promoters
Prospectus dated Wed 25 Mar 2026, page 22
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 59.67% | 43.26% |
Prospectus dated Wed 25 Mar 2026, page 82
Financials (restated)
| Item | October 31, 2025 | March 31, 2025 | March 31, 2024 | March 31, 2023 |
|---|---|---|---|---|
| Revenue from operations | ₹36.72 crore | ₹58.27 crore | ₹27.52 crore | ₹23.18 crore |
| Profit after tax | ₹6.06 crore | ₹8.61 crore | ₹2.93 crore | ₹1.70 crore |
| Net worth | ₹36.47 crore | ₹30.42 crore | ₹15.06 crore | ₹5.93 crore |
| Total borrowings | Not stated in the prospectus | Not stated in the prospectus | Not stated in the prospectus | Not stated in the prospectus |
Prospectus dated Wed 25 Mar 2026, page 60
SME issue facts
- The face value of each Equity Share is ₹ 10 and the Issue Price at the lower end of the Price Band is ₹ 117 per Equity Share and at the higher end of the Price Band is ₹ 124 per Equity Share. (Prospectus dated Wed 25 Mar 2026, page 315)
- the minimum contract size of 1000 Equity Shares (Prospectus dated Wed 25 Mar 2026, page 316)
- Allocation and allotment of Equity Shares through this Issue was done in multiples of 1000 Equity Share subject to a minimum allotment of 1000 Equity Shares to the successful Applicants. (Prospectus dated Wed 25 Mar 2026, page 316)
- the minimum application size in terms of number of specified securities was not less than two lots. (Prospectus dated Wed 25 Mar 2026, page 316)
- the minimum number of allottees in this Issue was 200 shareholders. (Prospectus dated Wed 25 Mar 2026, page 316)
Peer comparison (as in the Prospectus)
| Name of the Company | Face value (₹) | Revenue from operations (₹ in Lakhs) | Basic EPS (₹) | Diluted EPS (₹) | P/E (based on Diluted EPS) | Return on net worth (%) | NAV per Equity Shares (₹) |
|---|---|---|---|---|---|---|---|
| Speciality Medicines Limited | 10 | 5,827.14 | 14.10 | 14.10 | 8.79 | 28.42% | 47.26 |
| Remus Pharmaceuticals Limited | 10 | 62,036.00 | 65.21 | 65.21 | 10.41 | 15.02% | 434.25 |
| Trident Lifeline Limited | 10 | 8,696.47 | 10.22 | 10.22 | 27.00 | 18.23% | 56.05 |
| Mono Pharmacare Limited | 10 | 16,834.49 | 1.75 | 1.75 | 7.49 | 9.90% | 17.66 |
Reproduced from the Prospectus dated Wed 25 Mar 2026, pages 114 to 115; InsightPier adds no figures
Risk factors
73 total- Dependence on third-party suppliers for products (offer document page 29)
- Revenue concentrated among major customers (offer document page 29)
- Past negative operating cash flows (offer document page 30)
- No prior research and development experience (offer document page 31)
- Risks from international operations (offer document page 33)
All 73 risk factors, pages 28 to 55
Offer document
Allotment and bids
Registrar to the issue: SKYLINE FINANCIAL SERVICES PRIVATE LIMITED.
Allotment status was expected on the registrar's site from Wed 25 Mar 2026 and is not yet confirmed. Pick "SPECIALITY MEDICINES LIMITED" from the issue list there.
Subscription (final)
| Category | Shares offered | Shares bid for | Times subscribed |
|---|---|---|---|
| Overall | – | – | 2.34× |
ipocentral.in and ipowatch.in, as of Tue 17 Nov 2026